公开(公告)号：EP1751553A2

公开(公告)日：2007-02-14

申请号：EP05759896.3

申请日：2005-05-24

申请人： Ludwig-Maximilians-Universität München ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： BERTSCH, Uwe ,  GIESE, Armin ,  KRETZSCHMAR, Hans ,  TAVAN, Paul ,  HIRSCHBERGER, Thomas ,  BIESCHKE, Jan ,  WEBER, Petra ,  WINKLHOFER, Konstanze, F. ,  TATZELT, Jörg ,  HARTL, F., Ulrich ,  WÜNSCH, Gerda ,  HÖGEN, Tobias, Johannes

IPC分类号： G01N33/68 ,  A61K31/155 ,  C07C281/18 ,  C07C243/24 ,  A61K31/16

CPC分类号： G01N33/6896 ,  A61K31/155 ,  G01N2500/02 ,  G01N2500/10

摘要： The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.

公开(公告)号：EP1751553B1

公开(公告)日：2008-10-08

申请号：EP05759896.3

申请日：2005-05-24

申请人： Ludwig-Maximilians-Universität München ,  Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

发明人： BERTSCH, Uwe ,  GIESE, Armin ,  KRETZSCHMAR, Hans ,  TAVAN, Paul ,  HIRSCHBERGER, Thomas ,  BIESCHKE, Jan ,  WEBER, Petra ,  WINKLHOFER, Konstanze, F. ,  TATZELT, Jörg ,  HARTL, F., Ulrich ,  WÜNSCH, Gerda ,  HÖGEN, Tobias, Johannes

IPC分类号： G01N33/68 ,  A61K31/155 ,  C07C281/18 ,  C07C243/24 ,  A61K31/16

CPC分类号： G01N33/6896 ,  A61K31/155 ,  G01N2500/02 ,  G01N2500/10

摘要： The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.